Sapablursen - Ionis Pharmaceuticals
Alternative Names: IONIS TMPRSS6-Lrx; IONIS-TMPRSS6-LRx; ISIS-702843; ONO 0530Latest Information Update: 09 Dec 2025
At a glance
- Originator Ionis Pharmaceuticals
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action TMPRSS6 protein inhibitors
-
Orphan Drug Status
Yes - Polycythaemia vera
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Polycythaemia vera
- Discontinued Beta-thalassaemia; Thalassaemia
Most Recent Events
- 06 Dec 2025 Adverse events and efficacy data from a phase IIa trial in Polycythaemia vera released by Deciphera Pharmaceuticals
- 06 Dec 2025 Deciphera Pharmaceuticals plans a phase III trial for Polycythemia vera by the year 2026
- 31 May 2025 Sapablursen receives Breakthrough Therapy status for Polycythaemia vera in USA